Our latest news

Press Releases
In the News

Accelerator Life Science Partners Launches Biotechnology Startup Company in Singapore with $16M in Series A Commitments

September 27, 2023

KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate

September 18, 2023

KayoThera, Inc. Strengthens Financial Position with $5.2 Million in Grant and Expanded Series A Funding, Bringing Total Financial Support to $14 Million

July 19, 2023

KayoThera, Inc. Raises $8 Million in Series A Financing Led by Accelerator Life Science Partners to Develop Novel Cancer Immunotherapeutics

March 16, 2022

ALSP Orchid Acquisition Corporation I Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing January 10, 2022

January 6, 2022

ALSP Orchid Acquisition Corporation I Announces $172.5 Million Initial Public Offering

November 23, 2021

Accelerator Life Science Partners Mourns the Loss of Senior Advisor and Friend, Tadataka “Tachi” Yamada, M.D.

August 5, 2021

Accelerator Life Science Partners Expands Executive Team with Appointment of Alice Chen as Executive Vice President

June 24, 2021

Accelerator Life Science Partners’ Portfolio Company Lodo Therapeutics Acquired by Zymergen Inc.

May 28, 2021

Amgen to Acquire Rodeo Therapeutics Corporation

March 30, 2021

Proniras Corporation Announces National Institute on Drug Abuse (NIDA) Grant Award to Pursue Treatment for Opioid Withdrawal

September 17, 2020

Accelerator Life Science Partners Expands its Team of Advisors

September 9, 2020

Rodeo Therapeutics Nominates First-in-Class Oral Development Candidate for Inflammatory Bowel Disease

August 31, 2020

Lodo Therapeutics Acquires Conifer Point Pharmaceuticals

August 7, 2020

Lodo Therapeutics Names Serial Biotech Entrepreneur Dale Pfost as CEO and Adds Top Industry Veterans to Leadership Team

December 20, 2019

Magnolia Neurosciences Corporation Announces that its Subsidiary Receives $20 Million CPRIT Grant to Develop Novel Therapies to Treat Chemotherapy-Induced Neurological Conditions

August 27, 2018

Accelerator Life Science Partners Launches Magnolia Neurosciences Corporation with $31 Million Series A to Develop Targeted Neuroprotective Therapies

August 13, 2018

Accelerator Life Science Partners Broadens its Leadership Teams and Expands its Geographic Operations to San Diego and the Greater Los Angeles Area

May 15, 2018

Lodo Therapeutics Corporation Forms Multi-Target Strategic Collaboration with Genentech

May 9, 2018

Proniras Corporation Awarded Contract Worth Up to $89.5 Million from U.S. Biomedical Advanced Research and Development Authority to Develop Tezampanel as a Medical Countermeasure for Nerve Agent-Induced Seizures

April 27, 2018

Accelerator Life Science Partners Launches Proniras Corporation to Support Development of Tezampanel in the Treatment of Seizure Disorders

April 27, 2018

Accelerator Corporation Announces Key Senior Leadership Appointments and Name Change to Accelerator Life Science Partners

December 13, 2017

Accelerator Corporation Announces Series A Financing in Rodeo Therapeutics to Focus on Small-Molecule Regenerative Therapies

July 25, 2017

Accelerator Corporation Announces $7M Series A Investment in ApoGen Biotechnologies to Develop a New Class of Drugs Targeting Resistance to Cancer Therapy

December 12, 2016

Accelerator Corporation Expands Operations with New Research Institution Partners

October 20, 2016

https://www.biocentury.com/article/647638

Could Singapore become the next global biotech hub?

May 4, 2023

https://www.asiaone.com/business/clavystbio-launches-translate-life-sciences-breakthroughs-health-impact

ClavystBio launches to translate life sciences breakthroughs into health impact

September 15, 2022

https://www.businesstimes.com.sg/garage/temaseks-cla-real-estate-sets-up-life-sciences-investment-company

Temasek’s CLA Real Estate sets up life sciences investment company

September 15, 2022

https://www.biospace.com/article/amgen-to-buy-rodeo-therapeutics-in-721-million-deal/

In Second Acquisition this Month, Amgen Buys Rodeo for $721 Million

March 31, 2021

https://www.fiercebiotech.com/biotech/amgen-drops-55m-upfront-for-rodeo-therapeutics-and-its-prostaglandin-blockers

Amgen Saddles Up with Rodeo for a $55M Trek into Regenerative Medicine

March 31, 2021

https://endpts.com/amgen-takes-a-swing-at-regenerative-immunology-with-721m-acquisition-of-rodeo-therapeutics/

Amgen Takes a Swing at Regenerative Immunology with $721M Acquisition of Rodeo Therapeutics

March 30, 2021

https://timmermanreport.com/2021/03/amgen-acquires-rodeo-lean-startup-with-dual-mechanism-for-crohns-colitis/

Amgen Acquires Rodeo, Lean Startup With Dual Mechanisms for Crohn’s, Colitis

March 30, 2021

https://www.genengnews.com/insights/taking-aim-at-peripheral-neuropathy-and-neurodegeneration-targets/

Taking Aim at Peripheral Neuropathy and Neurodegeneration Targets

May 1, 2019

https://www.geekwire.com/2019/seattle-startup-rodeo-therapeutics-raises-cash-regenerative-medicine-treatments/

Seattle startup Rodeo Therapeutics raises more cash for regenerative medicine treatments

April 2, 2019

https://www.prnewswire.com/news-releases/alexandria-venture-investments-launches-the-alexandria-seed-capital-platform-a-novel-and-innovative-seed-stage-life-science-funding-model-and-a-natural-extension-of-alexandria-launchlabs-300578307.html

Alexandria Venture Investments Launches the Alexandria Seed Capital Platform, a Novel and Innovative Seed-Stage Life Science Funding Model and a Natural Extension of Alexandria LaunchLabs

January 8, 2018

https://www.geekwire.com/2017/accelerator-corp-announces-new-leadership-renames-accelerator-life-science-partners/